Compare AbbVie Inc (ABBV) vs ARK Autonomous Technology & Robotics ETF (ARKQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs ARK Autonomous Technology & Robotics ETF — how do they compare? AbbVie Inc trades at $253.68 (market cap $449.91B), while ARK Autonomous Technology & Robotics ETF trades at $123.06. The key difference: AbbVie Inc pays a 2.72% dividend while ARK Autonomous Technology & Robotics ETF pays none, and AbbVie Inc is trading nearer its 52-week high, ARK Autonomous Technology & Robotics ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | ARKQ | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | Sector/Thematic |
52-Week High | $261.07 | $143.82 |
52-Week Low | $184.85 | $88.47 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
ARKQ trades at $130.11, up 1.7% on the day, with a bearish technical signal from moving averages and neutral oscillators. The ETF focuses on autonomous technology and robotics, benefiting from AI momentum, with assets under management reaching $2.7 billion as of April 2026 (Seeking Alpha, 2026-04-26). Recent news highlights sector growth in AI, robotics, and autonomous vehicles, though valuation metrics like P/E are not provided in the current data.
Outlook remains tied to AI and robotics adoption, with potential from themes like humanoid robots and autonomous driving. Risks include high valuations, sector volatility, and reliance on tech spending. Analyst sentiment is mixed, with some upgrades citing growth potential but technical indicators suggesting near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About ARK Autonomous Technology & Robotics ETF
ARKQ is an actively managed ETF that invests in autonomous technology and robotics. It focuses on disruptive innovations like autonomous mobility, electric vehicles, 3D printing, and energy storage, with holdings such as Tesla and Teradyne.
Read more on ARKQ →
